Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 8.650-9.000 for the period, compared to the consensus EPS estimate of 8.020. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Halozyme Therapeutics Stock Up 2.6%

Shares of HALO traded up $2.17 during trading hours on Thursday, hitting $85.76. The company had a trading volume of 2,679,037 shares, compared to its average volume of 1,643,316. The firm has a fifty day moving average price of $75.74 and a 200-day moving average price of $71.25. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $86.00. The stock has a market capitalization of $10.17 billion, a price-to-earnings ratio of 30.85, a P/E/G ratio of 0.35 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the firm posted $1.54 EPS. The firm’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts forecast that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.60.

Insider Activity at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This trade represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 72,477 shares of company stock worth $5,102,643. 2.50% of the stock is owned by company insiders.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q2 results significantly exceeded expectations: Revenue rose 48% year over year to $481 million, versus the $402.28 million analyst consensus, while adjusted EPS of $2.28 surpassed estimates of $1.79 and increased from $1.54 a year earlier. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Royalty growth underscores the strength of Halozyme’s platform: Royalty revenue increased 50% year over year to $308 million. Management highlighted the repeatability, scalability, diversification and durability of the ENHANZE drug-delivery platform. Halozyme Q2 2026 Earnings Call Transcript
• Positive Sentiment: Full-year 2026 guidance was raised: Halozyme now expects revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP EPS of $8.65 to $9.00. The EPS outlook is above the approximately $8.02 consensus estimate. Halozyme 2026 Guidance Update
• Positive Sentiment: Business development momentum improved: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year target of three. The agreements potentially broaden future revenue and royalty opportunities. Halozyme Collaboration Agreements
• Neutral Sentiment: The strong results raise expectations for continued execution; investors will likely focus on whether new collaborations translate into durable commercial royalties and whether Halozyme can sustain its elevated growth rates.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HALO. Abel Hall LLC lifted its position in shares of Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 129 shares during the last quarter. StoneX Group Inc. grew its stake in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 132 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after buying an additional 165 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in shares of Halozyme Therapeutics by 0.8% in the third quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 184 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.